Royalty Pharma plc (NASDAQ:RPRX) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Royalty Pharma plc (NASDAQ:RPRX) have earned an average recommendation of “Buy” from the four brokerages that are currently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $46.75.

A number of brokerages have weighed in on RPRX. Bank of America decreased their target price on Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, April 12th. JPMorgan Chase & Co. decreased their target price on Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a research report on Tuesday, February 20th. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, April 11th. Finally, The Goldman Sachs Group decreased their target price on Royalty Pharma from $56.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, February 20th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. M&T Bank Corp grew its stake in Royalty Pharma by 2.5% during the 3rd quarter. M&T Bank Corp now owns 10,671 shares of the biopharmaceutical company’s stock worth $428,000 after buying an additional 259 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Royalty Pharma by 7.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,973 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 337 shares during the last quarter. Advisor Group Holdings Inc. grew its stake in Royalty Pharma by 9.4% during the 1st quarter. Advisor Group Holdings Inc. now owns 4,265 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 366 shares during the last quarter. Sei Investments Co. grew its stake in Royalty Pharma by 4.7% during the 1st quarter. Sei Investments Co. now owns 8,392 shares of the biopharmaceutical company’s stock worth $281,000 after buying an additional 379 shares during the last quarter. Finally, Ballentine Partners LLC grew its stake in Royalty Pharma by 3.3% during the 1st quarter. Ballentine Partners LLC now owns 12,541 shares of the biopharmaceutical company’s stock worth $381,000 after buying an additional 406 shares during the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Royalty Pharma Price Performance

NASDAQ:RPRX opened at $27.46 on Friday. The firm has a market capitalization of $16.41 billion, a price-to-earnings ratio of 14.53, a PEG ratio of 0.81 and a beta of 0.45. Royalty Pharma has a 1 year low of $25.92 and a 1 year high of $36.67. The business has a 50 day simple moving average of $29.84 and a 200-day simple moving average of $28.51. The company has a debt-to-equity ratio of 0.61, a current ratio of 7.90 and a quick ratio of 7.90.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.12. Royalty Pharma had a return on equity of 26.93% and a net margin of 48.22%. The firm had revenue of $736.00 million during the quarter, compared to analyst estimates of $702.90 million. Equities analysts forecast that Royalty Pharma will post 3.89 EPS for the current year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Friday, February 16th were issued a $0.21 dividend. The ex-dividend date was Thursday, February 15th. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.20. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.06%. Royalty Pharma’s dividend payout ratio (DPR) is currently 44.44%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.